VAN KARLYLE MORRIS

TitleAssistant Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol. 2021; 11:643815. PMID: 34367949.
      Citations:    
    2. Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, You YN, Taniguchi C, Koay EJ, Bednarski B, Rodriguez-Bigas M, Skibber J, Wolff R, Chang GJ, Minsky BD, Foo WC, Rothschild N, Morris VK, Eng C. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045. PMID: 34084278.
      Citations:    Fields:    
    3. Wiggins CJ, Morris VK, Klimas NK, Nagarajan P, Curry JL, Richards KN. Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1. JAAD Case Rep. 2021 Jul; 13:23-25. PMID: 34136620.
      Citations:    
    4. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5. PMID: 34250391.
      Citations: 1     
    5. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 Jun 01; 27(11):3039-3049. PMID: 33811152.
      Citations: 1     Fields:    
    6. Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 02 01; 113(2):208-211. PMID: 32294214.
      Citations: 9     Fields:    Translation:HumansCells
    7. Morris VK, Strickler JH. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annu Rev Med. 2021 01 27; 72:399-413. PMID: 33502901.
      Citations:    Fields:    
    8. Antonoff MB, Morris VK. Reply from author: Biology is king, but metastasectomy still has a role for properly selected patients. J Thorac Cardiovasc Surg. 2021 07; 162(1):e136-e138. PMID: 33419552.
      Citations:    Fields:    Translation:Humans
    9. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 02 01; 39(4):285-294. PMID: 33356422.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    10. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 06; 20(2):137-147.e1. PMID: 33229221.
      Citations: 1     Fields:    
    11. Noticewala SS, Ludmir EB, Eng C, Holliday EB, Minsky BD, Morris VK, Das P. Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiother Oncol. 2020 10; 151:56-57. PMID: 32710989.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    12. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770. PMID: 32632268.
      Citations: 24     Fields:    Translation:Humans
    13. Corsini EM, Mitchell KG, Correa A, Morris VK, Antonoff MB. Effect of primary colorectal cancer tumor location on survival after pulmonary metastasectomy. J Thorac Cardiovasc Surg. 2021 07; 162(1):296-305. PMID: 32713636.
      Citations: 1     Fields:    Translation:Humans
    14. Jácome AA, Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199. PMID: 32680816.
      Citations:    Fields:    
    15. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6. PMID: 32665092.
      Citations:    Fields:    
    16. Eng C, Fakih M, Amin M, Morris V, Hochster HS, Boland PM, Uronis H. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. Oncotarget. 2020 Apr 14; 11(15):1334-1343. PMID: 32341753.
      Citations: 1     Fields:    
    17. Morris VK, Bekaii-Saab T. Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer. Clin Cancer Res. 2020 09 01; 26(17):4435-4441. PMID: 32253230.
      Citations: 2     Fields:    
    18. Corsini EM, Datar SS, Mitchell KG, Zhou N, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Blackmon SH, Loree JM, Morris VK, Antonoff MB. High mutational concordance between primary colorectal tumors and associated pulmonary metastases. J Surg Oncol. 2020 May; 121(6):984-989. PMID: 32077113.
      Citations:    Fields:    Translation:Humans
    19. Chen E, Abu-Sbeih H, Thirumurthi S, Mallepally N, Khurana S, Wei D, Altan M, Morris VK, Tan D, Barcenas CH, Wang Y. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol. 2020 Jan-Feb; 33(1):59-67. PMID: 31892799.
      Citations: 3     
    20. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2. PMID: 32008976.
      Citations:    Fields:    Translation:HumansCells
    21. Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AAL, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami MA, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris V. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precis Oncol. 2019; 3. PMID: 33015522.
      Citations: 2     
    22. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510. PMID: 31406299.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    23. Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker? JAMA Oncol. 2019 Aug 01; 5(8):1101-1103. PMID: 31070713.
      Citations:    Fields:    
    24. Corsini EM, Mitchell KG, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Swisher SG, Roth JA, Hofstetter WL, Vaporciyan AA, Morris VK, Antonoff MB. Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. J Surg Oncol. 2019 Sep; 120(4):729-735. PMID: 31290159.
      Citations: 3     Fields:    Translation:Humans
    25. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010. PMID: 30854646.
      Citations: 29     Fields:    Translation:Humans
    26. Morris VK. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. Curr Colorectal Cancer Rep. 2019 Apr; 15(2):53-60. PMID: 31762713.
      Citations: 2     
    27. Morris VK. Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral. Clin Cancer Res. 2019 04 01; 25(7):2030-2032. PMID: 30655314.
      Citations: 2     Fields:    Translation:HumansCells
    28. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709. PMID: 30205948.
      Citations: 10     Fields:    Translation:HumansCells
    29. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072. PMID: 29180604.
      Citations: 52     Fields:    Translation:Humans
    30. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949. PMID: 28850629.
      Citations: 9     Fields:    Translation:Humans
    31. Morris V, Rao X, Pickering C, Foo WC, Rashid A, Eterovic K, Kim T, Chen K, Wang J, Shaw K, Eng C. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Mol Cancer Res. 2017 11; 15(11):1542-1550. PMID: 28784613.
      Citations: 16     Fields:    Translation:HumansAnimals
    32. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279. PMID: 28424412.
      Citations: 28     Fields:    Translation:Humans
    33. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453. PMID: 28223062.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    34. Morris V, Eng C. Metastatic Anal Cancer and Novel Agents. Surg Oncol Clin N Am. 2017 01; 26(1):133-142. PMID: 27889032.
      Citations: 1     Fields:    Translation:Humans
    35. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365. PMID: 27729313.
      Citations: 83     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    36. Morris V, Eng C. Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. J Gastrointest Oncol. 2016 Oct; 7(5):721-726. PMID: 27747086.
      Citations: 3     
    37. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631. PMID: 27421137.
      Citations: 18     Fields:    Translation:Humans
    38. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4032-8. PMID: 26460303.
      Citations: 204     Fields:    Translation:HumansCTClinical Trials
    39. Jauch SF, Morris VK, Jensen CT, Kaseb AO. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. Pancreatology. 2016 Jan-Feb; 16(1):153-6. PMID: 26456669.
      Citations: 3     Fields:    Translation:Humans
    40. Morris VK, Rashid A, Rodriguez-Bigas M, Das P, Chang G, Ohinata A, Rogers J, Crane C, Wolff RA, Eng C. Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. Oncologist. 2015 Nov; 20(11):1247-52. PMID: 26382740.
      Citations: 8     Fields:    Translation:HumansCells
    41. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8. PMID: 25535726.
      Citations: 27     Fields:    Translation:Humans
    42. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer. 2014 Sep 10; 14:660. PMID: 25208577.
      Citations: 8     Fields:    Translation:Humans
    43. Morris VK, Lucas FAS, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014. PMID: 25009008.
      Citations: 28     Fields:    Translation:Humans
    44. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71. PMID: 25069797.
      Citations: 37     Fields:    Translation:Humans
    45. Morris V, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol. 2013 Dec; 11(12):768-76. PMID: 24893280.
      Citations: 1     Fields:    Translation:Humans
    46. Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep. 2013; 5:11. PMID: 23585929.
      Citations: 12     
    47. Jabbour E, Morris V, Kantarjian H, Yin CC, Burton E, Cortes J. Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18; 120(16):3382-3. PMID: 23086624.
      Citations: 8     Fields:    Translation:Humans
    48. Morris VK, Spraker HL, Howard SC, Ware RE, Reiss UM. Severe thrombocytopenia with iron deficiency anemia. Pediatr Hematol Oncol. 2010 Aug; 27(5):413-9. PMID: 20670168.
      Citations: 6     Fields:    Translation:Humans
    49. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer. 114:1352-1361.
    50. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.
    51. BRAF Mutations in Non-Metastatic Colorectal Cancer. Current Colorectal Cancer Reports. 11:303-310.
    52. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas. Pancreatology. 16:153-156.
    53. MET amplification in metastatic colorectal cancer. Oncotarget. 7:54627-54631.
    54. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discovery. 6:1352-1365.
    55. Clinicopathologic features associated with human papillomavirus/pl6 in patients with metastatic squamous cell carcinoma of the anal canal. Oncologist. 20:1247-1252.
    56. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26:731-736.
    57. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. Journal of Clinical Oncology. 33:4032-4038.
    58. Metastatic Anal Cancer and Novel Agents. Surgical Oncology Clinics of North America. 26:133-142.
    59. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. Oncotarget. 7:67495-67506.
    MORRIS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (140)
    Explore
    _
    Co-Authors (79)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _